Myto Health will be successful by establishing partnership, collaboration and commercialization of its technologies. Myto Health has established a platform that is the source of many of the technologies and solutions.
The main premise of Myto Health is that Ubiquitin Proteasome System (UPS) is the central machine that drives many parts of cells such as mitochondrial health. Aggregation of misfolded proteins that cause mitochondrial dysfunction must be removed by UPS.
Because of the breadth and depth of the platform translation of these products and services into clinic requires highly accomplished teams. Myto Health plans to share, partner, establish joint ventures, license, and seek investments to bring these technologies to patients and consumers.
Myto Health’s technology platform and tools allow discovery development of drugs, nutraceuticals, and diagnostic tools to promote mitochondrial health, uncover susceptibility to neurodegeneration, and help clinicians select a patient population that responds to UPS mitochondrial targeting therapies.
We have created opportunities for establishing collaborations and partnerships with biotech companies as well as academic laboratories.
Joint Ventures • Platform Licensing • Co-Development
Five core pillars translating mitochondrial quality control into clinical diagnostics, targeted drug design, and longevity solutions.
Blood-based poly-ubiquitin platform identifying familial and sporadic neurodegenerative biomarkers for early detection.
Targeting ubiquitin E3 ligases to discover rational small molecules and GRAS-compliant nutraceuticals activating mitophagy.
Interrogating DNA sequencing and ligase mutations to predict mitochondrial vulnerability and tailor therapeutic response.
AI algorithm trained on thousands of genetic variants to predict protein structure, ligase activity, and disease risk.
Maintaining mitochondrial homeostasis and proteostasis to attenuate sarcopenia, combat aging, and extend healthspan.
We are particularly interested in sharing and partnering across three validated core platforms.
The diagnostic test has been validated with patients that have mutations in genes that lead to PD. Application of this test for late onset of PD diagnosis includes up to one million patients in the USA alone.
Currently there is no blood-based test for diagnosis of PD. The blood-based diagnostic signatures of poly-ubiquitins will have broad diagnostic applications for early detection of PD as well as aging markers.
By screening ubiquitin ligases that activate mitophagy and consequently mitobiogenesis we have discovered nutraceuticals that promote these functions.
Natural products can be marketed without FDA approval due to “GRAS” (Generally Recognized As Safe). Under sections 201(s) and 409 of the Federal Food, Drug, and Cosmetic Act, any substance intentionally added to food is a food additive.
To address poly-indication maladies we have screened small molecule libraries against ubiquitin ligases that promote mitophagy and mitobiogenesis to elevate these diseases.
Further medicinal chemistry of these molecules has improved potency and exposure on target tissues (brain). These molecules promote mitophagy, improve recovery from ischemic attack, with elucidated mechanisms of action.
Myto Health invites inquiries from collaborators, investors, and organizations to bring these technologies to patients.
